Search results
Showing 3551 to 3600 of 4089 results for patient
In development Reference number: GID-TA11689 Expected publication date: TBC
This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.
In development Reference number: GID-TA11345 Expected publication date: TBC
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726
In development Reference number: GID-TA11015 Expected publication date: TBC
In development Reference number: GID-TA11014 Expected publication date: TBC
In development Reference number: GID-MT594 Expected publication date: TBC
In development Reference number: GID-TA11523 Expected publication date: TBC
This guideline covers the period before, during and after a young person moves from children's to adults' services. It aims to help young people and their carers have a better experience of transition by improving the way it’s planned and carried out. It covers both health and social care.
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]
In development Reference number: GID-TA11070 Expected publication date: TBC
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
In development Reference number: GID-TA11189 Expected publication date: TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
In development Reference number: GID-TA11302 Expected publication date: TBC
Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]
Discontinued Reference number: GID-TA11522
In development Reference number: GID-TA11646 Expected publication date: TBC
In development Reference number: GID-TA11679 Expected publication date: TBC
Canagliflozin for treating type 2 diabetes in people 10 to 17 years [ID6352]
In development Reference number: GID-TA11377 Expected publication date: TBC
Discontinued Reference number: GID-TA11179
Discontinued Reference number: GID-MT130
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]
In development Reference number: GID-TA11629 Expected publication date: TBC
Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]
Discontinued Reference number: GID-TA11176
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued Reference number: GID-TA11178
In development Reference number: GID-TA11310 Expected publication date: TBC
Non-invasive skin closure devices for surgical incisions (MT775)
In development Reference number: GID-MT593 Expected publication date: TBC
In development Reference number: GID-TA11745 Expected publication date: TBC
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099
In development Reference number: GID-TA11640 Expected publication date: TBC
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]
Discontinued Reference number: GID-TA11712
Thousands could benefit from new take-at-home treatment for advanced prostate cancer
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment.
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
Discontinued Reference number: GID-TA10522
Discontinued Reference number: GID-TA11177
Discontinued Reference number: GID-TA11181
Oral semaglutide for managing overweight and obesity [ID6188]
Discontinued Reference number: GID-TA11149
In development Reference number: GID-TA11482 Expected publication date: TBC
Sacubitril valsartan for treating chronic heart failure with preserved ejection fraction [ID1606]
Discontinued Reference number: GID-TA11257
In development Reference number: GID-TA11627 Expected publication date: TBC
Etripamil for treating paroxysmal supraventricular tachycardia [ID6581]
In development Reference number: GID-TA11750 Expected publication date: TBC
In development Reference number: GID-TA11697 Expected publication date: TBC
Discontinued Reference number: GID-TA10707
Discontinued Reference number: GID-TA11171
Capecitabine for the treatment of advanced pancreatic cancer [ID127]
Discontinued Reference number: GID-TA11239
Discontinued Reference number: GID-TA11258
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055]
In development Reference number: GID-TA11272 Expected publication date: TBC
In development Reference number: GID-TA11274 Expected publication date: TBC
In development Reference number: GID-TA11273 Expected publication date: TBC
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]
In development Reference number: GID-TA11634 Expected publication date: TBC
In development Reference number: GID-TA11556 Expected publication date: TBC
In development Reference number: GID-TA11771 Expected publication date: TBC
In development Reference number: GID-TA11588 Expected publication date: TBC
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]
In development Reference number: GID-TA11781 Expected publication date: TBC
Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]
In development Reference number: GID-TA11848 Expected publication date: TBC
In development Reference number: GID-TA11327 Expected publication date: TBC
In development Reference number: GID-TA11831 Expected publication date: TBC